Nevro Corp (NVRO): Michael F Demane , director of Nevro Corp sold 13,333 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 12, 2016 to the Securities and Exchange Commission. The shares were sold at $79.00 per share for a total value of $1,053,307.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 7, 2016, Michael Enxing (VP of Sales) sold 1,500 shares at $75.52 per share price.On Jul 6, 2016, Michael F Demane (director) sold 13,333 shares at $74.00 per share price.Also, On Jun 10, 2016, Andre Walker (Senior VP,Research&Development) sold 6,000 shares at $76.00 per share price.On Jun 10, 2016, Rami Elghandour (President & CEO) sold 7,000 shares at $76.41 per share price.
Nevro Corp: On Monday, Jul 11, 2016 heightened volatility was witnessed in Nevro Corp which led to swings in the share price. The shares opened for trading at $78.75 and hit $80.055 on the upside , eventually ending the session at $79.54, with a gain of 1.64% or 1.28 points. The heightened volatility saw the trading volume jump to 6,92,313 shares. The 52-week high of the share price is $79 and the company has a market cap of $2,253 M . The 52-week low of the share price is at $36.51.
Company has been under the radar of several Street Analysts.Nevro Corp is Initiated by Wells Fargo to Outperform. The Rating was issued on Jul 12, 2016.
Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Company’s Senza system creates electrical impulses from two hertz to 10 kilohertz including its HF10 therapy which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads a trial stimulator an implantable pulse generator (IPG) surgical tools a clinician laptop programmer a patient remote control and a mobile charger.